Nomura Holdings
BCRX icon

Nomura Holdings’s BioCryst Pharmaceuticals BCRX Stock Holding History

Nomura Holdings’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$903K Buy
94,900
+53,900
+131% +$419K ﹤0.01% 1194
2025
Q4 		$320K Buy
+41,000
New +$296K ﹤0.01% 1655

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Nomura Holdings's BCRX Position: Q1 2023 in Review

Nomura Holdings sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2023, closing a stake of 1,328,291 shares — an estimated $15.2M sold.

Nomura Holdings first reported a position in BCRX in Q2 2013 and held it in 5 quarters. The position peaked at $15.2M in Q4 2022. 241 funds tracked by Wall St. Rank hold BCRX as of Q1 2023.

  • Nomura Holdings reported no remaining BioCryst Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Nomura Holdings sold 1,328,291 BioCryst Pharmaceuticals shares in Q1 2023, an estimated $15.2M.
  • Nomura Holdings first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Nomura Holdings's BioCryst Pharmaceuticals position peaked at $15.2M in Q4 2022.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2023.

Based on Nomura Holdings's 13F filing for Q1 2023, filed 15 May 2023.